Comparison of short‐course versus long‐course antibiotic treatment for community‐acquired pneumonia: a meta-analysis of randomized control trials
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233123Keywords:
CAP, PRISMA, PneumoniaAbstract
The duration of antibiotic treatment of community acquired pneumonia (CAP) has been a topic of discussion in scientific communities because of the lack of evidence about the current regimen, i.e., 7 to 10 days of treatment. The present meta-analysis aims to compare the effectiveness of shorter-duration antibiotic treatment with longer-duration antibiotic treatment in patients with CAP. This meta-analysis was conducted and reported in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Two authors carried out a scientific literature search on online databases, including EMBASE, PubMed and Cochrane Library. The following keywords or corresponding medical subject headings (MeSH) were used for the search of relevant articles: “community-acquired pneumonia”, “antibiotics”, “drug therapy”, “short course”, “long course”, and "duration". The primary outcomes assessed in this meta-analysis were clinical efficacy, microbiological efficacy and radiological resolution, other outcomes included mortality and drug related adverse events. Total 6 RCTs were included in the current meta-analysis. No significant differences were found between shorter-course and longer-course antibiotic treatment in terms of clinical efficacy, microbiological efficiency, radiological resolution, mortality and drug-related adverse events. The findings of the present meta-analysis showed that the treatment of CAP with a shorter course of antibiotic is as effective as a longer course of therapy.
Metrics
References
López‐Alcalde J, Rodriguez‐Barrientos R, Redondo‐Sánchez J et al. Short‐course versus long‐course therapy of the same antibiotic for community‐acquired pneumonia in adolescent and adult outpatients. Cochrane Database of Systematic Reviews. 2018;9(9):CD009070.pub2.
World Health Organization. The top ten causes of death. 2019. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin. 2004;1:761-76.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;1:71-9.
Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM et al. The epidemic of antibiotic‐resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-64.
Torres A, Barberán J, Falguera M, Menéndez R, Molina J, Olaechea P et al. Grupo de la Guía Multidisciplinar para el Manejo de la Neumonía Adquirida en la Comunidad. Guía multidisciplinar para la valoración pronóstica, diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Med Clín. 2013;140(5):223-1.
Kaysin A, Viera AJ. Community-acquired pneumonia in adults: diagnosis and management. Am Family Physician. 2016;94(9):698-706.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell JD, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(2):27-72.
Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;18:340.
Chalmers JD, Akram AR, Singanayagam A, Wilcox MH, Hill AT. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect. 2016;1(2):45-53.
Longcor J, Hopkins S, Wickler M, Laurence L. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). ID week. 2012;17(2):17-21.
Dinh A, Bouchand F, Salomon J, Bernard L. Short-course antibiotic regimens: up-to-date. La Revue de Med Interne. 2016;8(4):466-72.
Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM et al. High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradig. Clin Infect Dis. 2003;37(6):752-60.
File Jr TM, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemoth. 2007;60(1):112-20.
El Moussaoui R, De Borgie CA, Van den Broek P, Hustinx WN, Bresser P, Van den Berk GEL et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double-blind study. BMJ. 2006;332(7554):1355.
Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Internal Med. 2016;176(9):1257-65.
Zhao T, Chen LA, Wang P, Tian G, Ye F, Zhu H et al. A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia. J Thoracic Dis. 2016;8(9):2473.
Zhao X, Wu JF, Xiu QY, Wang C, De-Ping Z, Jian-An H et al. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia. Diagnostic Microbiol Infect Dis. 2014;80(2):141-7.
Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2018;62(9):e00635-18.
Casey JR, Pichichero ME. Meta-analysis of short course antibiotic treatment for group a Streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2005;24:909-17.
Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588-98.
Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respiratory Dis. 1993;147(1):38-44.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respiratory Crit Care Med. 2019;200(7):45-67.
Spellberg B. The new antibiotic mantra-“shorter is better”. JAMA Internal Med. 2016;176:1254-5.
Branthwaite AJ, Pechère JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res. 1996;24:229-38.
Hoppe JE, Blumenstock G, Grotz W, Med C, Selbmann HK. Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey. The. Pediatr Infect Dis J. 1999;18:1085-91.
Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;294(5):365-70.
Dawson-Hahn EE, Mickan S, Onakpoya I, Roberts N, Kronman M, Butler CC et al. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Family practice. 2017;34(5):511-9.
Møller Gundersen K, Nygaard Jensen J, Bjerrum L, Hansen MP. Short‐course vs long‐course antibiotic treatment for community‐acquired pneumonia: A literature review. Basic Clin Pharmacol Toxicol. 2019;124:550-9.
